Advanced search
1 file | 1.69 MB Add to list

Androgen therapy does not prevent bone loss and arterial calcifications in male rats with chronic kidney disease

Author
Organization
Abstract
Patients suffering from chronic kidney disease (CKD) often experience bone loss and arterial calcifications. It is unclear if hypogonadism contributes to the development of these complications, and whether androgen therapy might prevent them. Male adult rats were randomized into 4 groups. The first group received standard chow (Control), while three other groups were fed a 0.25% adenine/low vitamin K diet (CKD). Two CKD groups were treated with testosterone (T) or dihydrotestosterone (DHT), whereas the control group and one CKD group received vehicle (VEH). CKD animals had 10-fold higher serum creatinine and more than 15-fold higher PTH-levels compared to controls. Serum T levels were more than 2-fold lower in the CKD-VEH group compared to Control-VEH and CKD-T groups. Seminal vesicle weight was reduced by 50% in CKD-VEH animals, and restored by T and DHT. CKD animals showed a low bone mass phenotype with decreased trabecular bone volume fraction and increased cortical porosity, which was not rescued by androgen treatment. Aortic calcification was much more prominent in CKD animals and not unequivocally prevented by androgens. Messenger RNA expression of the androgen receptor-responsive genes Acta1 and Col1a1 was reduced by CKD and stimulated by androgen treatment in levator ani muscle, but not in bone or aortic tissue. We conclude that adenine-induced CKD results in the development of hypogonadism in male rats. Androgen therapy is effective in restoring serum T levels and androgen-sensitive organ weights, but does not prevent bone loss or arterial calcifications, at least not in the presence of severe hyperparathyroidism.
Keywords
Endocrinology, Endocrinology, Diabetes and Metabolism

Downloads

  • Androgen therapy CKD rats JOE - Lirias.pdf
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.69 MB

Citation

Please use this url to cite or link to this publication:

MLA
David, Karel, et al. “Androgen Therapy Does Not Prevent Bone Loss and Arterial Calcifications in Male Rats with Chronic Kidney Disease.” JOURNAL OF ENDOCRINOLOGY, vol. 257, no. 3, Bioscientifica, 2023, doi:10.1530/joe-22-0319.
APA
David, K., Dubois, V., Verhulst, A., Sommers, V., Schollaert, D., Deboel, L., … Decallonne, B. (2023). Androgen therapy does not prevent bone loss and arterial calcifications in male rats with chronic kidney disease. JOURNAL OF ENDOCRINOLOGY, 257(3). https://doi.org/10.1530/joe-22-0319
Chicago author-date
David, Karel, Vanessa Dubois, Anja Verhulst, Vera Sommers, Dieter Schollaert, Ludo Deboel, Karen Moermans, et al. 2023. “Androgen Therapy Does Not Prevent Bone Loss and Arterial Calcifications in Male Rats with Chronic Kidney Disease.” JOURNAL OF ENDOCRINOLOGY 257 (3). https://doi.org/10.1530/joe-22-0319.
Chicago author-date (all authors)
David, Karel, Vanessa Dubois, Anja Verhulst, Vera Sommers, Dieter Schollaert, Ludo Deboel, Karen Moermans, Geert Carmeliet, Patrick D’Haese, Dirk Vanderschueren, Frank Claessens, Pieter Evenepoel, and Brigitte Decallonne. 2023. “Androgen Therapy Does Not Prevent Bone Loss and Arterial Calcifications in Male Rats with Chronic Kidney Disease.” JOURNAL OF ENDOCRINOLOGY 257 (3). doi:10.1530/joe-22-0319.
Vancouver
1.
David K, Dubois V, Verhulst A, Sommers V, Schollaert D, Deboel L, et al. Androgen therapy does not prevent bone loss and arterial calcifications in male rats with chronic kidney disease. JOURNAL OF ENDOCRINOLOGY. 2023;257(3).
IEEE
[1]
K. David et al., “Androgen therapy does not prevent bone loss and arterial calcifications in male rats with chronic kidney disease,” JOURNAL OF ENDOCRINOLOGY, vol. 257, no. 3, 2023.
@article{01GW9M17MJM31MZ4WRM1TTFCMV,
  abstract     = {{Patients suffering from chronic kidney disease (CKD) often experience bone loss and arterial calcifications. It is unclear if hypogonadism contributes to the development of these complications, and whether androgen therapy might prevent them. Male adult rats were randomized into 4 groups. The first group received standard chow (Control), while three other groups were fed a 0.25% adenine/low vitamin K diet (CKD). Two CKD groups were treated with testosterone (T) or dihydrotestosterone (DHT), whereas the control group and one CKD group received vehicle (VEH). CKD animals had 10-fold higher serum creatinine and more than 15-fold higher PTH-levels compared to controls. Serum T levels were more than 2-fold lower in the CKD-VEH group compared to Control-VEH and CKD-T groups. Seminal vesicle weight was reduced by 50% in CKD-VEH animals, and restored by T and DHT. CKD animals showed a low bone mass phenotype with decreased trabecular bone volume fraction and increased cortical porosity, which was not rescued by androgen treatment. Aortic calcification was much more prominent in CKD animals and not unequivocally prevented by androgens. Messenger RNA expression of the androgen receptor-responsive genes Acta1 and Col1a1 was reduced by CKD and stimulated by androgen treatment in levator ani muscle, but not in bone or aortic tissue. We conclude that adenine-induced CKD results in the development of hypogonadism in male rats. Androgen therapy is effective in restoring serum T levels and androgen-sensitive organ weights, but does not prevent bone loss or arterial calcifications, at least not in the presence of severe hyperparathyroidism.}},
  articleno    = {{e220319}},
  author       = {{David, Karel and Dubois, Vanessa and Verhulst, Anja and Sommers, Vera and Schollaert, Dieter and Deboel, Ludo and Moermans, Karen and Carmeliet, Geert and D'Haese, Patrick and Vanderschueren, Dirk and Claessens, Frank and Evenepoel, Pieter and Decallonne, Brigitte}},
  issn         = {{0022-0795}},
  journal      = {{JOURNAL OF ENDOCRINOLOGY}},
  keywords     = {{Endocrinology,Endocrinology, Diabetes and Metabolism}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Bioscientifica}},
  title        = {{Androgen therapy does not prevent bone loss and arterial calcifications in male rats with chronic kidney disease}},
  url          = {{http://doi.org/10.1530/joe-22-0319}},
  volume       = {{257}},
  year         = {{2023}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: